Health Immunotherapy-Chemo Offers Survival Advantage in Low PD-L1 NSCLC Eli Pacheco Sep 23, 2021 0 Adding durvalumab (Imfinzi) and tremelimumab to chemotherapy improved progression-free and overall survival…
